Nivolumab (Opdyta) Price in India 2026: Per Vial, Biosimilar Tishtha and What Drives Total Cost
Quick answer: At its January 2026 launch, Zydus Lifesciences priced its nivolumab biosimilar, Tishtha, at ₹28,950 for a 100 mg vial and ₹13,950 for a 40 mg vial, and described this as about one-fourth of the reference product’s price. The original brand is sold in India as Opdyta. A vial price is only one building block: your dose, the number of cycles, day-care charges and monitoring decide what a family actually pays.
Medically reviewed by: [Reviewer name, qualification] | Last reviewed: [DD Month YYYY]
What is nivolumab, and what is it called in India?
Nivolumab is a PD-1 immune checkpoint inhibitor, given as an intravenous infusion. It works by blocking a protein called PD-1 on T-cells, which can help the immune system recognise cancer cells in some patients. If you would like the background first, our guide to immune checkpoint inhibitors explains the mechanism and the usual side effects.
Outside India the originator is widely known as Opdivo. In India, the regulator’s records list the originator brand as Opdyta, marketed by Bristol-Myers Squibb India, in 40 mg, 100 mg and 240 mg presentations. This matters for budgeting: foreign price lists for Opdivo do not tell you what Opdyta or a domestic biosimilar costs here.
Published nivolumab prices in India (2026)
The only widely published, dated price points we could verify come from the biosimilar’s launch announcement on 22 January 2026. Zydus said the biosimilar was launched after the Delhi High Court cleared its sale.
| Product | Strength | Published price | Source and date |
|---|---|---|---|
| Tishtha (nivolumab biosimilar, Zydus) | 100 mg vial | ₹28,950 | Manufacturer launch announcement, 22 Jan 2026 |
| Tishtha (nivolumab biosimilar, Zydus) | 40 mg vial | ₹13,950 | Manufacturer launch announcement, 22 Jan 2026 |
| Opdyta (originator) | 40 mg, 100 mg, 240 mg | Not published as a single list price; reported as roughly four times the biosimilar | Manufacturer statement that the biosimilar is about one-fourth of the reference price |
These are launch-time figures, not hospital quotes. Prices change, and the amount a hospital pharmacy charges can differ from the published vial price. Always ask for a current, itemised quotation.
Why online listings can mislead you
Searching for nivolumab online turns up trade and distributor listings with wildly inconsistent prices for what appears to be the same product, including listings that name Opdivo, Opdyta or a bare molecule name without a brand. Prices that look too low may signal a product of unknown origin; this is a cold-chain biologic that must be stored under controlled conditions. The safer route is to obtain the medicine through the treating hospital’s own pharmacy, check the batch and packaging, and keep the bill.
From vial price to treatment cost: what really drives the bill
Families often multiply a vial price and assume the total. In practice, the cost of a nivolumab course depends on several things your oncologist decides or your hospital sets:
- Dose and vials per infusion. Dosing may be weight-based or a fixed dose depending on the cancer and schedule. One infusion may need more than one vial, and part of a vial can go unused.
- Number and spacing of cycles. Treatment is reviewed at intervals and may continue, change or stop earlier than first planned. A course is not a fixed number at the start.
- Brand choice. Originator or biosimilar, where your oncologist considers either suitable for your situation.
- Day-care and administration charges. These vary by hospital and are usually billed on top of the drug.
- Monitoring. Blood tests, thyroid and liver checks and scans to review response and side effects are part of safe treatment.
- Combination partners. Nivolumab is sometimes given with another immunotherapy or with chemotherapy, which adds to the total.
A simple illustration of the arithmetic
This is arithmetic, not a dosing example. If a prescribed dose happened to need one 100 mg vial and one 40 mg vial, the two published biosimilar launch prices would add up to ₹42,900 for the drug alone for that infusion, before day-care and monitoring. Your own dose could need fewer or more vials, which is why only your treating oncologist can tell you what a cycle will involve.
Which cancers is nivolumab used for in India?
Approval in India is granted indication by indication, never for a molecule as a whole. Published regulatory material from the originator’s India programme lists uses such as non-small cell lung cancer after prior chemotherapy, advanced renal cell carcinoma after prior therapy, recurrent or metastatic head and neck squamous cell carcinoma after platinum-based therapy, urothelial carcinoma after platinum-containing chemotherapy, and MSI-high or mismatch-repair-deficient metastatic colorectal cancer after specific earlier drugs. Labels are updated over time. In September 2026 the Indian regulator’s oncology expert committee also reviewed a proposal related to nivolumab in untreated stage III or IV classical Hodgkin lymphoma. Approved uses in India depend on the current CDSCO label, so ask your oncologist which indication applies to you.
For a fuller list by cancer type, see our overview of checkpoint inhibitors in India. If your prescription is for pembrolizumab instead, read our Keytruda price guide.
Biosimilar or originator: questions to ask your oncologist
A biosimilar contains the same active molecule as the reference medicine and is approved by the regulator on the basis of comparison with it. A lower price does not widen the group of people nivolumab is suitable for, and most people with cancer are not candidates for a checkpoint inhibitor at all. Useful questions:
- Is nivolumab appropriate for my cancer type and stage, and is my use covered by the current label?
- Would you consider the biosimilar for me, and is there any reason to prefer the originator?
- How many vials will each infusion need, and how often will my response be reviewed?
- What side effects should we watch for, and whom do we call at night or on weekends?
Our guide on who is eligible for immunotherapy covers this decision in more depth.
Planning for the cost: insurance, schemes and written quotes
Whether a policy or scheme pays for nivolumab depends on the policy wording, the approved indication, pre-authorisation and the hospital’s empanelment. Ask your insurer in writing whether your specific use is covered, and ask the hospital for an itemised estimate that separates drug cost, day-care charge and monitoring tests. A single bundled per-cycle figure cannot be compared fairly with a published vial price. Our article on financial assistance for cancer treatment lists routes families commonly explore, and our immunotherapy cost overview shows how drug choice affects totals.
How Denvax can help
Denvax Cancer Center in Vasant Vihar, New Delhi, has treated over 25,000 patients since 2004. We offer chemotherapy, radiotherapy, targeted therapy and dendritic cell immunotherapy. We do not offer cancer testing, screening or diagnostics, and we are not a surgical centre, so please bring your existing reports and prescription. At a consultation our doctors can discuss which treatment options are relevant to your reports and what to ask your treating team about immunotherapy medicines and costs.
Frequently asked questions
Is Opdivo available in India?
The originator nivolumab is registered in India under the brand name Opdyta. Some websites advertise “Opdivo” vials; treat such listings with caution and source medicines through your hospital pharmacy.
How much does a nivolumab biosimilar cost in India?
Zydus announced Tishtha at ₹28,950 for a 100 mg vial and ₹13,950 for a 40 mg vial in January 2026. These are launch prices, not hospital quotes, and the cost per infusion depends on your dose.
Is a biosimilar the same as the original medicine?
It contains the same active molecule and is approved on the basis of comparison with the reference product, but it is made by a different manufacturer. Whether it is suitable for you is your oncologist’s decision.
Does health insurance cover nivolumab?
It depends on your policy, the approved indication, pre-authorisation and the hospital. Ask your insurer for written confirmation before starting treatment.
How long does nivolumab treatment last?
It varies by cancer type, schedule and how you respond and tolerate treatment. Your oncologist reviews it at intervals and may continue, change or stop it, so the number of cycles is not fixed at the start.
Results may vary. Consult your oncologist. This article is for general information and is not medical advice. Prices are published launch figures and may have changed.
Talk to a Denvax doctor about your treatment options
Bring your reports and prescription to a consultation at Denvax Cancer Center, 18 Poorvi Marg, Vasant Vihar, New Delhi 110057.
अपनी रिपोर्ट और पर्चे के साथ Denvax Cancer Center में परामर्श के लिए संपर्क करें।
- Immunotherapy for Kidney Cancer in India: Options, Who May Be Eligible and Cost Factors
- When Chemotherapy Stops Working: Next Treatment Options in India
